Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.

Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R.

J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

2.

Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models.

Borsi E, Martello M, Santacroce B, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Rocchi S, Cavo M, Terragna C.

Haematologica. 2018 Dec;103(12):e602-e606. doi: 10.3324/haematol.2017.186924. Epub 2018 Jul 19. No abstract available.

3.

Multiple myeloma: disease response assessment.

Zamagni E, Tacchetti P, Terragna C, Cavo M.

Expert Rev Hematol. 2016 Sep;9(9):831-7. doi: 10.1080/17474086.2016.1212654. Epub 2016 Jul 25. Review.

PMID:
27409577
4.

Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.

Martello M, Remondini D, Borsi E, Santacroce B, Procacci M, Pezzi A, Dico FA, Martinelli G, Zamagni E, Tacchetti P, Pantani L, Testoni N, Marzocchi G, Rocchi S, Zannetti BA, Mancuso K, Cavo M, Terragna C.

Leukemia. 2016 Sep;30(9):1869-76. doi: 10.1038/leu.2016.77. Epub 2016 Apr 14.

PMID:
27074969
5.

Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.

Tacchetti P, Cavo M, Rocchi S, Pezzi A, Pantani L, Brioli A, Testoni N, Terragna C, Zannetti BA, Mancuso K, Marzocchi G, Borsi E, Martello M, Rizzello I, Zamagni E.

Leuk Lymphoma. 2016 Sep;57(9):2058-64. doi: 10.3109/10428194.2015.1124994. Epub 2016 Jan 14.

PMID:
26763357
6.

Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.

Pantani L, Brioli A, Tacchetti P, Zannetti BA, Mancuso K, Rocchi S, Martello M, Rizzello I, Terragna C, Zamagni E, Cavo M.

Expert Rev Hematol. 2016 Mar;9(3):315-23. doi: 10.1586/17474086.2016.1127754. Epub 2015 Dec 28. Review.

PMID:
26634945
7.

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).

Terragna C, Remondini D, Martello M, Zamagni E, Pantani L, Patriarca F, Pezzi A, Levi G, Offidani M, Proserpio I, De Sabbata G, Tacchetti P, Cangialosi C, Ciambelli F, Viganò CV, Dico FA, Santacroce B, Borsi E, Brioli A, Marzocchi G, Castellani G, Martinelli G, Palumbo A, Cavo M.

Oncotarget. 2016 Mar 1;7(9):9666-79. doi: 10.18632/oncotarget.5718.

8.

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.

Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, Zannetti B, Rambaldi I, Brioli A, Rocchi S, Terragna C, Martello M, Marzocchi G, Borsi E, Rizzello I, Fanti S, Cavo M.

Clin Cancer Res. 2015 Oct 1;21(19):4384-90. doi: 10.1158/1078-0432.CCR-15-0396. Epub 2015 Jun 15.

9.

Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.

Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C, Marzocchi G, Santoro A, Cavo M.

Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035.

10.

Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.

Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M, Cavo M.

Transl Res. 2015 Jun;165(6):641-50. doi: 10.1016/j.trsl.2014.12.001. Epub 2014 Dec 11. Review.

PMID:
25553605
11.

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.

Borsi E, Perrone G, Terragna C, Martello M, Zamagni E, Tacchetti P, Pantani L, Brioli A, Dico AF, Zannetti BA, Rocchi S, Cavo M.

Exp Cell Res. 2014 Nov 1;328(2):444-55. doi: 10.1016/j.yexcr.2014.09.018. Epub 2014 Sep 26.

PMID:
25257607
12.

Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.

Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V, Martello M, Tosi P, Baldini L, Peccatori J, Ruggieri M, Pantani L, Lazzaro A, Elice F, Rocchi S, Gozzetti A, Cavaletti G, Palumbo A, Cavo M.

Am J Hematol. 2014 Dec;89(12):1085-91. doi: 10.1002/ajh.23835. Epub 2014 Sep 17.

13.

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.

Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, Caltagirone S, Grasso M, Rossini F, Guglielmelli T, Cangialosi C, Liberati AM, Callea V, Carovita T, Crippa C, De Rosa L, Pisani F, Falcone AP, Pregno P, Oliva S, Terragna C, Musto P, Passera R, Boccadoro M, Palumbo A.

Leukemia. 2015 Mar;29(3):689-95. doi: 10.1038/leu.2014.219. Epub 2014 Jul 16.

PMID:
25027515
14.

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.

Borsi E, Perrone G, Terragna C, Martello M, Dico AF, Solaini G, Baracca A, Sgarbi G, Pasquinelli G, Valente S, Zamagni E, Tacchetti P, Martinelli G, Cavo M.

Oncotarget. 2014 Apr 15;5(7):1779-92.

15.

Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma.

Zamagni E, Nanni C, Tacchetti P, Pantani L, Marzocchi G, Zannetti B, Terragna C, Mancuso K, Rocchi S, Pezzi A, Testoni N, Fanti S, Cavo M.

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):e101-4. doi: 10.1016/j.clml.2013.12.014. Epub 2013 Dec 26. No abstract available.

PMID:
24508412
16.

Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.

Terragna C, Renzulli M, Remondini D, Tagliafico E, Di Raimondo F, Patriarca F, Martinelli G, Roncaglia E, Masini L, Tosi P, Zamagni E, Tacchetti P, Ledda A, Brioli A, Angelucci E, Testoni N, Marzocchi G, Galieni P, Gozzetti A, Martello M, Dico F, Mancuso K, Cavo M.

Ann Hematol. 2013 Sep;92(9):1271-80. doi: 10.1007/s00277-013-1757-6. Epub 2013 May 10.

PMID:
23660628
17.

Cap dependent translation contributes to resistance of myeloma cells to bortezomib.

Mancino M, Grosso S, Terragna C, Borsi E, Cavo M, Biffo S.

Translation (Austin). 2013 Nov 18;1(2):e27245. doi: 10.4161/trla.27245. eCollection 2013.

18.

Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.

Zamagni E, Petrucci A, Tosi P, Tacchetti P, Perrone G, Brioli A, Pantani L, Zannetti B, Terragna C, Baccarani M, Cavo M.

Ann Hematol. 2012 Mar;91(3):419-26. doi: 10.1007/s00277-011-1320-2. Epub 2011 Sep 8.

PMID:
21901342
19.

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M.

Blood. 2011 Dec 1;118(23):5989-95. doi: 10.1182/blood-2011-06-361386. Epub 2011 Sep 6. Erratum in: Blood. 2012 Sep 13;120(11):2349.

20.

c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells.

Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C, Durante S, Valli E, Kalebic T, Bernardoni R, Perrod C, Haber M, Norris MD, Baccarani M, Martinelli G, Perini G.

Mol Cancer Res. 2011 Aug;9(8):1054-66. doi: 10.1158/1541-7786.MCR-10-0510. Epub 2011 Jun 21.

21.

Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.

Tosi P, Terragna C, Testoni N, Zamagni E, Renzulli M, Tacchetti P, Montanari E, Perrone G, Ceccolini M, Brioli A, Pallotti MC, Tura S, Baccarani M, Cavo M.

Eur J Haematol. 2008 Jan;80(1):31-6. Epub 2007 Nov 23.

PMID:
18036184
22.

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.

Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.

Br J Haematol. 2007 Nov;139(3):415-24.

PMID:
17910631
23.

Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging.

Isidori A, Motta MR, Tani M, Terragna C, Zinzani P, Curti A, Rizzi S, Taioli S, Giudice V, D'Addio A, Gugliotta G, Conte R, Baccarani M, Lemoli RM.

Biol Blood Marrow Transplant. 2007 Oct;13(10):1224-32. Epub 2007 Aug 24.

24.

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.

Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.

J Clin Oncol. 2006 Jan 20;24(3):454-9.

PMID:
16421422
25.

Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.

Cavo M, Terragna C, Renzulli M, Zamagni E, Tosi P, Testoni N, Nicci C, Cangini D, Tacchetti P, Grafone T, Cellini C, Ceccolini M, Perrone G, Martinelli G, Baccarani M, Guardigni L.

J Clin Oncol. 2006 Jan 20;24(3):e4-5. No abstract available.

PMID:
16421414
26.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, de Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M; Bologna 2002 study.

Blood. 2005 Jul 1;106(1):35-9. Epub 2005 Mar 10.

27.

Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.

Curti A, Isidori A, Ferri E, Terragna C, Neyroz P, Cellini C, Ratta M, Baccarani M, Lemoli RM.

Leuk Lymphoma. 2004 Jul;45(7):1419-28.

PMID:
15359643
28.

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

Bianchini M, Ottaviani E, Grafone T, Giannini B, Soverini S, Terragna C, Amabile M, Piccaluga PP, Malagola M, Rondoni M, Bosi C, Baccarani M, Martinelli G.

Clin Chem. 2003 Oct;49(10):1642-50.

29.

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Blood. 2003 Sep 1;102(5):1927-9. Epub 2003 May 8.

30.

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Bonifazi F, Neri A, Fabris S, Tura S, Baccarani M, Martinelli G.

Blood. 2003 Sep 1;102(5):1588-94. Epub 2003 May 1.

31.

Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely.

Martinelli G, Buonamici S, Visani G, Malagola M, Piccaluga PP, Isidori A, Bosi C, Bonifazi F, Soverini S, Terragna C, Amabile M, Giannini B, Baccarani M.

Leukemia. 2003 Mar;17(3):650-1; author reply 651-2. No abstract available.

PMID:
12646962
32.

Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade.

Arpinati M, Terragna C, Chirumbolo G, Rizzi S, Urbini B, Re F, Tura S, Baccarani M, Rondelli D.

Exp Hematol. 2003 Jan;31(1):31-8.

PMID:
12543104
33.

Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.

Soverini S, Terragna C, Testoni N, Ruggeri D, Tosi P, Zamagni E, Cellini C, Cavo M, Baccarani M, Tura S, Martinelli G.

Haematologica. 2002 Oct;87(10):1036-40.

34.
35.

Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage.

Re F, Arpinati M, Testoni N, Ricci P, Terragna C, Preda P, Ruggeri D, Senese B, Chirumbolo G, Martelli V, Urbini B, Baccarani M, Tura S, Rondelli D.

Exp Hematol. 2002 Feb;30(2):126-34.

PMID:
11823047
36.

Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.

Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, Amabile M, Terragna C, Ruggeri D, Piccaluga PP, Isidori A, Malagola M, Baccarani M, Tura S, Martinelli G.

Blood. 2002 Jan 15;99(2):443-9.

37.

Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.

Amabile M, Giannini B, Testoni N, Montefusco V, Rosti G, Zardini C, Terragna C, Buonamici S, Ottaviani E, Soverini S, Fiacchini M, Bassi S, de Vivo A, Trabacchi E, Saglio G, Pane F, Baccarani M, Tura S, Martinelli G.

Haematologica. 2001 Mar;86(3):252-9.

38.

Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.

Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli R, Bandini G, Testoni N, Amabile M, Ottaviani E, Buonamici S, Soverini S, Montefusco V, de Vivo A, Bonifazi F, Tura S, Cavo M.

Haematologica. 2000 Sep;85(9):930-4.

39.

Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.

Martinelli G, Montefusco V, Amabile M, Lemoli RM, Terragna C, Testoni N, Ottaviani E, Rosti G, de Vivo A, Rizzi S, Russo D, Bregoli M, Tura S.

Leuk Lymphoma. 2000 Sep;39(1-2):113-20.

PMID:
10975389
40.

Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma.

Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P, Lemoli RM, Benni M, Pagliani G, Bandini G, Tura S.

Blood. 2000 Jul 1;96(1):355-7.

41.

Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.

Martinelli G, Montefusco V, Testoni N, Amabile M, Saglio G, Ottaviani E, Terragna C, Bonifazi F, Rosti G, Bandini G, Tura S.

Haematologica. 2000 Jun;85(6):653-8.

42.

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma.

Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, Bandini G, Motta MR, Testoni N, Amabile M, Ottaviani E, Vianelli N, de Vivo A, Gozzetti A, Tura S, Cavo M.

J Clin Oncol. 2000 Jun;18(11):2273-81.

PMID:
10829048
43.

Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.

Martinelli G, Testoni N, Amabile M, Bonifazi F, De Vivo A, Farabegoli P, Terragna C, Montefusco V, Ottaviani E, Saglio G, Russo D, Baccarani M, Rosti G, Tura S.

Bone Marrow Transplant. 2000 Apr;25(7):729-36.

44.

Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy.

Lemoli RM, Martinelli G, Zamagni E, Motta MR, Rizzi S, Terragna C, Rondelli R, Ronconi S, Curti A, Bonifazi F, Tura S, Cavo M.

Blood. 2000 Apr 1;95(7):2234-9.

45.

Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.

Martinelli G, Terragna C, Amabile M, Montefusco V, Testoni N, Ottaviani E, de Vivo A, Mianulli A, Saglio G, Tura S.

Haematologica. 2000 Jan;85(1):40-6.

46.

Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study.

Lemoli RM, Martinelli G, Olivieri A, Motta MR, Rizzi S, Terragna C, Leopardi G, Benni M, Ronconi S, Cantori I, Rondelli D, Mangianti S, Leoni P, Montanari M, Cavo M, Tura S.

Br J Haematol. 1999 Nov;107(2):419-28.

PMID:
10583236
47.

Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2)

Martinelli G, Terragna C, Amabile M, Montefusco V, Testoni N, Ottaviani E, de Vivo A, Mianulli A, Trabacchi E, Saglio G, Tura S.

Leukemia. 1999 Oct;13(10):1635-7. No abstract available.

PMID:
10516770
48.

Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures.

Martinelli G, Ottaviani E, Testoni N, Visani G, Terragna C, Amabile M, Trabacchi E, Montefusco V, Tura S.

Bone Marrow Transplant. 1999 Sep;24(6):694-7. No abstract available.

49.

Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient.

Martinelli G, Amabile M, Terragna C, Testoni N, Ottaviani E, Montefusco V, de Vivo A, Baccarani M, Ricci P, Saglio G, Tura S.

Leukemia. 1999 Sep;13(9):1463-4. No abstract available.

PMID:
10483000
50.

An atypical (b3/a3) junction of the bcr/abl gene lacking abl exon a2 in a patient with chronic myeloid leukemia.

Amabile M, Martinelli G, Terragna C, Montefusco V, Tabilio A, Tura S.

Haematologica. 1999 Jun;84(6):573-5. No abstract available.

Supplemental Content

Loading ...
Support Center